Provided by Accuray Research LLP.
The Global Organ-On-Chip Market is poised to grow at a CAGR of around 69.4% over the next decade to reach approximately $6.13 billion by 2025.
Some of the predominant drivers in this market include growing applications of OOC's across several industries, increasing demand for OOC's in drug screening, recent technological advancements in organ-on-chip and government funding. However, regulatory hurdles for drug approvals and technical issues related to PDMS are some of the factors restraining the market growth.
The market is segmented by application into research, agriculture, chemicals, cosmetics, pharmaceutical, agrochemicals, consumer goods, nutraceuticals and food and beverages. The pharmaceutical segment commanded the largest market revenue in 2015, owing to the immediate need for OOCs in the preclinical testing of drugs. With more extensive development of this kind of chip, pharmaceutical companies will potentially be able to measure the direct effects of one organ’s reaction to another. The technology also shows significant potential for drug screening and lead optimization. But it is the agriculture segment that is expected to grow at the highest CAGR of 73.9% during the forecast period.
Organ-on-chip models could result in a paradigm shift for biomedical research and the pharmaceutical industry, leading to new ways to identify effective drugs and improving the quality of medical care for many prevalent and severe diseases. They could provide near-human test systems for (pre)clinical trials with high relevance for individual patients. This would facilitate the development of novel treatment modalities, and allow assessment of the impact of inflammation and the immune system on treatments and disease. In turn, this could accelerate drug entry into the market and lower their costs. An example is the Cytostretch chip, on which human stem cell-derived heart cells stretch at the frequency of the beating heart at rest or during exercise. Exercise-induced arrhythmias precipitated by drugs a common failure of clinical trials could be detected early in the drug development process. Organs-on-chips will also make personalized medicine possible.
North America commanded the largest market revenue in 2015. The USA accounts for the dominant share of the North American market. The presence in this region of several potential end users, including the major pharmaceutical giants Pfizer, GlaxoSmithKline, Johnson and Johnson, and major research organizations makes it account for a large part of the global market. The provision of high-scale funding by several US government organizations including National Institutes of Health (NIH) and Defense Advanced Research Projects Agency (DARPA) also supports research in the USA.
However Asia Pacific is expected to grow at the highest CAGR during the forecast period. Rapid aging in population, a rising number of people suffering from organ failures and a lack of donor organs for those individuals in need are some of the factors contributing to the growth of the market in this region.
Some of the key players in this market are:
Stay up-to-date with the latest market developments, trending news stories and industry advances with the Research and Markets blog. Don’t forget to join our mailing list to receive alerts for the latest blog plus information about new products.